Fractyl Health

Fractyl Health is a Burlington, Massachusetts-based biotechnology and healthcare company focused on metabolic diseases, particularly obesity and type 2 diabetes. Founded in 2010 by physician-scientist Harith Rajagopalan and Jay Caplan as Fractyl Laboratories, the company has pursued interventions intended to alter disease biology rather than rely solely on chronic systemic medication. Its principal clinical and commercial-development program is Revita, an outpatient endoscopic procedure designed to resurface the mucosal lining of the duodenum. The procedure uses water and controlled heat to ablate the existing lining, after which a new mucosal layer can regrow. Fractyl has argued that chronic exposure to high-fat and high-sugar diets can produce abnormalities in the duodenal lining and impair gastrointestinal signaling related to glucose regulation, insulin sensitivity, and metabolic control. By modifying this tissue, Revita is intended to improve metabolic signaling in people with type 2 diabetes and, more recently, to help people with obesity maintain weight after treatment with a GLP-1 medicine. Revita received European CE marking in April 2016 and became commercially available in the United Kingdom in January 2020. In April 2021, the United States Food and Drug Administration granted the device breakthrough-device designation for the treatment of type 2 diabetes. The FDA authorized an investigational device exemption study in April 2022, allowing the company to conduct a regulated U.S. clinical trial. Revita became commercially available in Germany in early 2023. In July 2024, the FDA granted an additional breakthrough-device designation for use related to weight maintenance in certain people with type 2 diabetes or obesity. Fractyl's second major platform is Rejuva, an investigational gene-therapy approach based on adeno-associated viral vectors. The platform is designed to deliver genetic material to pancreatic tissue so that selected pancreatic cells can produce glucagon-like peptide-1, or GLP-1, on an ongoing basis. The proposed approach seeks to provide durable endogenous GLP-1 production rather than require repeated injections or other recurring dosing. Rejuva remained preclinical in the available reference material; the company reported that its clinical-trial-application-enabling in-vivo studies had been completed in January 2025, with first-in-human work planned for the first half of 2025. Fractyl Health changed its name from Fractyl Laboratories to Fractyl Health in June 2021. It completed an initial public offering on Nasdaq in February 2024. In January 2025, the company said it would concentrate Revita research more heavily on obesity and on people taking GLP-1 drugs, reflecting the expanding use of GLP-1 therapies and the commercial need for approaches that could support weight maintenance after initial weight loss. The change in emphasis was accompanied by reductions in personnel working primarily on type 2 diabetes applications. As a development-stage biotechnology company, Fractyl's value proposition rests on transforming metabolic-disease care through tissue remodeling and potentially durable gene-based treatment, while its programs remain subject to clinical, regulatory, and commercial uncertainty.

Fractyl Health was established in 2010 by Harith Rajagopalan, MD, PhD, and Jay Caplan under the name Fractyl Laboratories. From the beginning, the company focused on metabolic diseases, including obesity and type 2 diabetes, and sought to develop interventions aimed at mechanisms in the gastrointestinal tract and pancreas. The company's leading program became Revita, an outpatient endoscopic procedure intended to remodel the duodenal mucosa. Revita uses controlled water and thermal energy to remove the existing mucosal surface. Fractyl's development rationale is that chronic dietary exposure and metabolic disease can alter the duodenal lining and disrupt signals involved in glucose homeostasis and insulin sensitivity. Following treatment, a new mucosal layer is expected to grow back, potentially restoring more favorable metabolic signaling. Revita received CE marking in April 2016. The procedure subsequently became commercially available in the United Kingdom in January 2020. In April 2021, the FDA designated Revita a breakthrough device for the treatment of type 2 diabetes. Fractyl Laboratories adopted the name Fractyl Health in June 2021, reflecting a broader healthcare and metabolic-disease identity. In April 2022, the FDA approved an investigational device exemption trial for Revita. The authorization supported the company's effort to generate U.S. clinical evidence under regulatory oversight. Revita became commercially available in Germany in early 2023. In July 2024, the FDA issued another breakthrough-device designation, this time covering weight-maintenance applications for certain people with type 2 diabetes or obesity. Fractyl also developed Rejuva, an AAV-based gene-therapy platform intended to enable pancreatic tissue to produce GLP-1 continuously. The proposed treatment uses a needle catheter to deliver viral vectors to the pancreas and is designed to target dysfunctional beta-islet cells. Unlike conventional GLP-1 medicines that require recurring administration, Rejuva is intended as a potentially durable biological intervention. The platform remained in preclinical development in the available reference material. In January 2025, Fractyl stated that it had completed in-vivo studies designed to support a future clinical-trial application and expected to begin first-in-human studies during the first half of 2025. Fractyl Health entered the public markets through an initial public offering on Nasdaq in February 2024. By early 2025, the company was reassessing the clinical and commercial priorities for Revita. In January 2025 it announced that research would focus more strongly on obesity and on people receiving GLP-1 treatment, including the possibility of using Revita to support weight maintenance after a patient has used a GLP-1 drug. The change reflected the rapid expansion of GLP-1 medicines and interest in solutions to weight regain. The company also reduced its workforce in areas primarily dedicated to type 2 diabetes treatment. Fractyl's history therefore combines device development, regulatory progression, international commercialization, public-market financing, and a strategic shift toward obesity-care applications.

• 2025

  Strategic focus shifts toward obesity and GLP-1 users

  [1]Fractyl Healthen.wikipedia.org

  Fractyl announced a stronger focus on obesity, weight maintenance, and patients using GLP-1 medicines.

• 2024

  Initial public offering

  [1]Fractyl Healthen.wikipedia.org

  Fractyl Health completed an initial public offering on Nasdaq in February.

• 2024

  Additional FDA breakthrough designation for Revita

  [1]Fractyl Healthen.wikipedia.org

  The FDA granted Revita another breakthrough-device designation in July for weight maintenance in certain people with type 2 diabetes or obesity.

• 2023

  Revita becomes available in Germany

  [1]Fractyl Healthen.wikipedia.org

  Revita entered commercial availability in Germany in early 2023.

• 2022

  FDA authorizes a Revita investigational device exemption trial

  [1]Fractyl Healthen.wikipedia.org

  The FDA approved an investigational device exemption trial for Revita in April.

• 2021

  Revita receives FDA breakthrough-device designation

  [1]Fractyl Healthen.wikipedia.org

  The FDA designated Revita a breakthrough device for treating type 2 diabetes in April; the company adopted the Fractyl Health name in June.

• 2020

  Revita becomes available in the United Kingdom

  [1]Fractyl Healthen.wikipedia.org

  The procedure became commercially available in the UK in January.

• 2016

  Revita receives CE marking

  [1]Fractyl Healthen.wikipedia.org

  Revita obtained European CE marking in April, an important regulatory milestone for the endoscopic device.

• 2010

  Company founded as Fractyl Laboratories

  [1]Fractyl Healthen.wikipedia.org

  Harith Rajagopalan and Jay Caplan established the company to pursue metabolic-disease therapies.

A metabolic-health biotechnology company pursuing durable, disease-modifying approaches to obesity and type 2 diabetes, including an endoscopic duodenal-resurfacing procedure and an investigational pancreatic GLP-1 gene-therapy platform.

• Endoscopic metabolic therapy · 2016

  Revita

  Revita is an outpatient endoscopic procedure that resurfaces the mucosal lining of the duodenum using controlled ablation with water and heat. Fractyl's scientific rationale is that chronic high-fat and high-sugar dietary exposure can thicken or otherwise impair the duodenal lining and disrupt metabolic signaling. After treatment, a healthier mucosal layer can regrow. The program has been studied for type 2 diabetes and has increasingly been directed toward weight maintenance in people with obesity or type 2 diabetes after GLP-1 treatment.

• AAV-based gene-therapy platform

  Rejuva

  Rejuva is an investigational adeno-associated virus gene-therapy platform intended to enable pancreatic cells to produce GLP-1 continuously. The proposed approach uses a catheter and needle to deliver viral vectors to the pancreas, with a focus on dysfunctional beta-islet cells. It is being developed as a potentially durable treatment for obesity and type 2 diabetes rather than a repeatedly administered GLP-1 medicine. The platform was preclinical in the available reference material.

• 2025

  Prioritize obesity and GLP-1-related weight maintenanceStrategy

  Background

  The expanding use of GLP-1 medicines increased demand for approaches that might help patients maintain weight loss after treatment.

  Action taken

  Fractyl redirected Revita research toward obesity and patients using GLP-1 therapies, while reducing some personnel focused on type 2 diabetes applications.

  Aftermath

  The decision made obesity and post-GLP-1 weight maintenance the more prominent development focus for Revita.

  Source

1. 1Fractyl Healthen.wikipedia.org